SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,626.70 (-3.15%)
DOW   29,185.90 (-2.48%)
QQQ   268.21 (-4.13%)
AAPL   139.61 (-4.00%)
MSFT   233.57 (-5.36%)
META   132.85 (-4.47%)
GOOGL   98.48 (-2.90%)
AMZN   114.18 (-5.09%)
TSLA   223.03 (-6.34%)
NVDA   120.81 (-7.99%)
NIO   13.74 (-6.97%)
BABA   80.93 (-4.02%)
AMD   58.67 (-13.53%)
T   14.91 (-2.68%)
MU   52.66 (-3.59%)
CGC   2.83 (-24.53%)
F   12.14 (-1.78%)
GE   64.28 (-2.93%)
DIS   96.62 (-3.42%)
AMC   6.50 (-8.71%)
PYPL   89.94 (-4.74%)
PFE   41.95 (-2.65%)
NFLX   225.47 (-6.06%)
S&P 500   3,626.70 (-3.15%)
DOW   29,185.90 (-2.48%)
QQQ   268.21 (-4.13%)
AAPL   139.61 (-4.00%)
MSFT   233.57 (-5.36%)
META   132.85 (-4.47%)
GOOGL   98.48 (-2.90%)
AMZN   114.18 (-5.09%)
TSLA   223.03 (-6.34%)
NVDA   120.81 (-7.99%)
NIO   13.74 (-6.97%)
BABA   80.93 (-4.02%)
AMD   58.67 (-13.53%)
T   14.91 (-2.68%)
MU   52.66 (-3.59%)
CGC   2.83 (-24.53%)
F   12.14 (-1.78%)
GE   64.28 (-2.93%)
DIS   96.62 (-3.42%)
AMC   6.50 (-8.71%)
PYPL   89.94 (-4.74%)
PFE   41.95 (-2.65%)
NFLX   225.47 (-6.06%)
S&P 500   3,626.70 (-3.15%)
DOW   29,185.90 (-2.48%)
QQQ   268.21 (-4.13%)
AAPL   139.61 (-4.00%)
MSFT   233.57 (-5.36%)
META   132.85 (-4.47%)
GOOGL   98.48 (-2.90%)
AMZN   114.18 (-5.09%)
TSLA   223.03 (-6.34%)
NVDA   120.81 (-7.99%)
NIO   13.74 (-6.97%)
BABA   80.93 (-4.02%)
AMD   58.67 (-13.53%)
T   14.91 (-2.68%)
MU   52.66 (-3.59%)
CGC   2.83 (-24.53%)
F   12.14 (-1.78%)
GE   64.28 (-2.93%)
DIS   96.62 (-3.42%)
AMC   6.50 (-8.71%)
PYPL   89.94 (-4.74%)
PFE   41.95 (-2.65%)
NFLX   225.47 (-6.06%)
S&P 500   3,626.70 (-3.15%)
DOW   29,185.90 (-2.48%)
QQQ   268.21 (-4.13%)
AAPL   139.61 (-4.00%)
MSFT   233.57 (-5.36%)
META   132.85 (-4.47%)
GOOGL   98.48 (-2.90%)
AMZN   114.18 (-5.09%)
TSLA   223.03 (-6.34%)
NVDA   120.81 (-7.99%)
NIO   13.74 (-6.97%)
BABA   80.93 (-4.02%)
AMD   58.67 (-13.53%)
T   14.91 (-2.68%)
MU   52.66 (-3.59%)
CGC   2.83 (-24.53%)
F   12.14 (-1.78%)
GE   64.28 (-2.93%)
DIS   96.62 (-3.42%)
AMC   6.50 (-8.71%)
PYPL   89.94 (-4.74%)
PFE   41.95 (-2.65%)
NFLX   225.47 (-6.06%)
NASDAQ:UTHR

United Therapeutics - UTHR Stock Forecast, Price & News

$206.50
-3.30 (-1.57%)
(As of 10/7/2022 03:28 PM ET)
Add
Compare
Today's Range
$206.50
$208.76
50-Day Range
$203.30
$231.07
52-Week Range
$158.38
$245.48
Volume
9,322 shs
Average Volume
365,761 shs
Market Capitalization
$9.40 billion
P/E Ratio
15.63
Dividend Yield
N/A
Price Target
$250.14

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
21.1% Upside
$250.14 Price Target
Short Interest
Healthy
2.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.38
Upright™ Environmental Score
News Sentiment
0.22mentions of United Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$7.95 M Sold Last Quarter
Proj. Earnings Growth
9.53%
From $14.90 to $16.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

168th out of 1,075 stocks

Pharmaceutical Preparations Industry

61st out of 537 stocks

UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

United Therapeutics (NASDAQ: UTHR)
United Therapeutics (UTHR) Q2 Earnings Lag Estimates
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
8/03/2022
Today
10/07/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$250.14
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+21.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$475.80 million
Pretax Margin
44.96%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$11.36 per share
Book Value
$87.90 per share

Miscellaneous

Free Float
39,872,000
Market Cap
$9.40 billion
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Dr. Martine A. Rothblatt J.D.Dr. Martine A. Rothblatt J.D. (Age 67)
    M.B.A., Ph.D., Founder, Chairman & CEO
    Comp: $3.51M
  • Mr. Michael I. Benkowitz (Age 50)
    Pres & COO
    Comp: $1.96M
  • Mr. James C. Edgemond (Age 54)
    CFO & Treasurer
    Comp: $1.42M
  • Mr. Paul A. Mahon J.D.Mr. Paul A. Mahon J.D. (Age 58)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $1.67M
  • Mr. Dewey Steadman C.F.A.
    Head of Investor Relations
  • Ms. Holly Hobson
    Associate VP of HR
  • Kevin T. Gray
    Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson (Age 54)
    Exec. VP of Technical Operations
  • Mr. Gil Golden
    Sr. VP & Chief Medical Officer
  • Dr. Leigh Peterson
    VP of Product Devel.













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2022?

7 equities research analysts have issued 1-year price targets for United Therapeutics' shares. Their UTHR share price forecasts range from $203.00 to $300.00. On average, they expect the company's stock price to reach $250.14 in the next year. This suggests a possible upside of 20.5% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2022?

United Therapeutics' stock was trading at $216.08 at the beginning of 2022. Since then, UTHR stock has decreased by 4.0% and is now trading at $207.51.
View the best growth stocks for 2022 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, August, 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing analysts' consensus estimates of $4.10 by $1.69. The biotechnology company had revenue of $466.90 million for the quarter, compared to the consensus estimate of $461.06 million. United Therapeutics had a net margin of 35.27% and a trailing twelve-month return on equity of 15.50%. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.65 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include New England Research & Management Inc. (0.01%), Symmetry Partners LLC (0.01%) and Exchange Traded Concepts LLC (0.01%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $207.51.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $9.45 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $13.21 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.